Literature DB >> 27789571

European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk.

Ulf Landmesser1, M. John Chapman2, Michel Farnier3, Baris Gencer4, Stephan Gielen5, G Kees Hovingh6, Thomas F Lüscher7, David Sinning1, Lale Tokgözoglu8, Olov Wiklund9, Jose Luis Zamorano10, Fausto J Pinto11, Alberico L Catapano12.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27789571     DOI： 10.1093/eurheartj/ehw480

Source DB:  PubMed          Journal:  Eur Heart J        ISSN： 0195-668X            Impact factor:   29.983


× No keyword cloud information.
  35 in total

Review 1.  Low Density Lipoprotein (LDL) Cholesterol as a Causal Role for Atherosclerotic Disease: Potential Role of PCSK9 Inhibitors.

Authors:  Rita Del Pinto; Davide Grassi; Giuliana Properzi; Giovambattista Desideri; Claudio Ferri
Journal:  High Blood Press Cardiovasc Prev       Date:  2019-06-24

Review 2.  Alirocumab as add-on therapy to statins: current evidence and clinical potential.

Authors:  Johann Auer; Robert Berent
Journal:  Ther Adv Cardiovasc Dis       Date:  2018-05-24

3.  Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial.

Authors:  Sabina A Murphy; Terje R Pedersen; Zbigniew A Gaciong; Richard Ceska; Marat V Ezhov; Derek L Connolly; J Wouter Jukema; Kalman Toth; Matti J Tikkanen; Kyungah Im; Stephen D Wiviott; Christopher E Kurtz; Narimon Honarpour; Robert P Giugliano; Anthony C Keech; Peter S Sever; Marc S Sabatine
Journal:  JAMA Cardiol       Date:  2019-07-01       Impact factor: 14.676

Review 4.  Diabetic Dyslipidemia: Epidemiology and Prevention of Cardiovascular Disease and Implications of Newer Therapies.

Authors:  Haider J Warraich; Jamal S Rana
Journal:  Curr Cardiol Rep       Date:  2018-10-11       Impact factor: 2.931

Review 5.  [ECS guidelines 2016 - dyslipidaemias].

Authors:  D Sinning; U Landmesser
Journal:  Herz       Date:  2016-12       Impact factor: 1.443

Review 6.  Regulation of poly(ADP-ribose) metabolism by poly(ADP-ribose) glycohydrolase: where and when?

Authors:  M-E Bonicalzi; J-F Haince; A Droit; G G Poirier
Journal:  Cell Mol Life Sci       Date:  2005-04       Impact factor: 9.261

Review 7.  Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis.

Authors:  Eliano P Navarese; Jennifer G Robinson; Mariusz Kowalewski; Michalina Kolodziejczak; Felicita Andreotti; Kevin Bliden; Udaya Tantry; Jacek Kubica; Paolo Raggi; Paul A Gurbel
Journal:  JAMA       Date:  2018-04-17       Impact factor: 56.272

Review 8.  Usefulness of alirocumab and evolocumab for the treatment of patients with diabetic dyslipidemia.

Authors:  Jun Zhang; Kristen M Tecson; Natalia A Rocha; Peter A McCullough
Journal:  Proc (Bayl Univ Med Cent)       Date:  2018-04-11

Review 9.  [Dyslipidemias : Diagnostics and management].

Authors:  D Sinning; U Landmesser
Journal:  Herz       Date:  2017-09       Impact factor: 1.443

Review 10.  Beyond conventional secondary prevention in coronary artery disease-what to choose in the era of CANTOS, COMPASS, FOURIER, ODYSSEY and PEGASUS-TIMI 54? A review on contemporary literature.

Authors:  Daniel Kalbacher; Christoph Waldeyer; Stefan Blankenberg; Dirk Westermann
Journal:  Ann Transl Med       Date:  2018-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.